Genakumab
PreclinicalMonoclonal antibody
Changchun GeneScience Pharmaceutical Co., Ltd.Genakumab is one of 15 small molecule programs targeting Systemic Juvenile Idiopathic Arthritis. It is currently in Preclinical.
1
Indications
9
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Systemic Juvenile Idiopathic Arthritis
#DrugCompanyPhaseTrials
1Actemra
RochePhase 3
Ilaris
NovartisPhase 3
Nsaids
RocheApproved
Olumiant
Eli LillyPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Rinvoq
AbbViePhase 3
ACZ885
NovartisPhase 3
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
RochePhase 3
Mra(tocilizumab)
RochePhase 3
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Malignant Solid Tumors1 trial
3 more indications
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Genakumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details